Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday

We recently published a list of These 10 Stocks Already Sank in June. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other worst performers on Monday.

Corcept Therapeutics dropped for a third consecutive day on Monday, shedding 7.58 percent to end at $71.68 apiece as investors appeared to have taken early profits from its intra-day surge.

At intra-day trading, Corcept Therapeutics Incorporated (NASDAQ:CORT) rallied to as high as $86.02 following news that its pivotal Phase 3 ROSELLA trial for the treatment of ovarian cancer achieved its primary endpoint of improved progression-free survival.

Investors booked early profits to pull the company’s share price down toward the end of the session.

Corcept Therapeutics Incorporated (NASDAQ:CORT) said that patients who received relacorilant combined with nab-paclitaxel chemotherapy, experienced a 30 percent reduction in risk of disease progression, compared with patients who received nab-paclitaxel monotherapy.

An interim analysis of overall survival (OS), showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients’ lives.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.